All In Biotech

Drug Trial Radar · NCT00996372

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States

Last checked: Nov 20, 2026Latest source record: Jun 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 949 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

949

Actual

Start

Oct 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Oct 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • flibanserinDrug

    patients will be randomized to flibanserin or placebo in a double-blind manner

  • placeboDrug

    patients will be randomized to flibanserin or placebo in a double-blind manner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Number of Satisfying Sexual EventsTime frame: baseline through 24 weeks
  2. Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire DomainTime frame: baseline through 24 weeks

Locations

75 sites in 1 country. Site status is shown where the registry gives one.

  • 511.130.01074 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 511.130.01046 Boehringer Ingelheim Investigational Site

    Huntsville, Alabama

  • 511.130.01042 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.130.01025 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 511.130.01073 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 511.130.01030 Boehringer Ingelheim Investigational Site

    Encinitas, California

  • 511.130.01028 Boehringer Ingelheim Investigational Site

    Fair Oaks, California

  • 511.130.01037 Boehringer Ingelheim Investigational Site

    Irvine, California

  • 511.130.01022 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 511.130.01035 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.130.01052 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.130.01016 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 511.130.01021 Boehringer Ingelheim Investigational Site

    Vista, California

  • 511.130.01051 Boehringer Ingelheim Investigational Site

    Westlake Village, California

  • 511.130.01071 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 511.130.01053 Boehringer Ingelheim Investigational Site

    Farmington, Connecticut

  • 511.130.01015 Boehringer Ingelheim Investigational Site

    Groton, Connecticut

  • 511.130.01041 Boehringer Ingelheim Investigational Site

    New Britain, Connecticut

  • 511.130.01064 Boehringer Ingelheim Investigational Site

    Newark, Delaware

  • 511.130.01062 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 511.130.01003 Boehringer Ingelheim Investigational Site

    Boynton Beach, Florida

  • 511.130.01056 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 511.130.01065 Boehringer Ingelheim Investigational Site

    Daytona Beach, Florida

  • 511.130.01020 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 511.130.01024 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 511.130.01070 Boehringer Ingelheim Investigational Site

    New Port Richey, Florida

  • 511.130.01043 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 511.130.01019 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 511.130.01061 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 511.130.01066 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 511.130.01001 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 511.130.01002 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 511.130.01009 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 511.130.01023 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 511.130.01008 Boehringer Ingelheim Investigational Site

    Sandy Springs, Georgia

  • 511.130.01044 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 511.130.01034 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 511.130.01067 Boehringer Ingelheim Investigational Site

    Lafayette, Louisiana

  • 511.130.01013 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 511.130.01031 Boehringer Ingelheim Investigational Site

    Bingham Farms, Michigan

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.